Neurofibromin

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 22: Line 22:
In the transition from the closed state to the open state, several of the domains of neurofibromin rotate to make the binding site of neurofibromin more accessible . This rotation is able to occur due to the rotation of three connective linkers, L1, L2, and L3. L1 is located between an alpha helix 48 in N-HEAT and an alpha helix 49 in GRD. G1190 is a potential hinge point when L1 rotates and pushes the alpha helixes outwards to move the Gap-related domain. L3 is located between the Sec14-PH domain and the C-HEAT/ARM and aids in the movement of the Sec14-PH domain. Without this rotation, the membrane binding sites are occluded and inaccessible. The proximity of L1 and L3 has to be close to facilitate the rotation of the domains.
In the transition from the closed state to the open state, several of the domains of neurofibromin rotate to make the binding site of neurofibromin more accessible . This rotation is able to occur due to the rotation of three connective linkers, L1, L2, and L3. L1 is located between an alpha helix 48 in N-HEAT and an alpha helix 49 in GRD. G1190 is a potential hinge point when L1 rotates and pushes the alpha helixes outwards to move the Gap-related domain. L3 is located between the Sec14-PH domain and the C-HEAT/ARM and aids in the movement of the Sec14-PH domain. Without this rotation, the membrane binding sites are occluded and inaccessible. The proximity of L1 and L3 has to be close to facilitate the rotation of the domains.
====SPRED-1 Protein====
====SPRED-1 Protein====
-
The SPRED-1 protein <scene name='90/904325/Nf1_ras_spred1/2'>localizes neurofibromin</scene> to the cell membrane in to allow it to bind to the membrane oriented Ras protein<ref name= ''Naschberger''>PMID:34707296</ref>. <scene name='90/904325/Spred_1/1'>SPRED-1</scene> interacts with the N-terminal domain of NF to guide it to the membrane from the cytosol, where its C terminal domain will determine its target <ref name= ''Dunzendorfer-Matt''>PMID:27313208</ref>.
+
The SPRED-1 protein <scene name='90/904325/Nf1_ras_spred1/2'>localizes neurofibromin</scene> to the cell membrane in to allow it to bind to the membrane oriented Ras protein<ref name= ''Naschberger''>PMID:34707296</ref>. <scene name='90/904325/Spred_1/2'>SPRED-1</scene> interacts with the N-terminal domain of NF to guide it to the membrane from the cytosol, where its C terminal domain will determine its target <ref name= ''Dunzendorfer-Matt''>PMID:27313208</ref>.
====Ras binding site====
====Ras binding site====

Revision as of 19:27, 14 April 2022

Neurofibromin (7pgs) Homo dimeric structure colored to differentiate dimers

Drag the structure with the mouse to rotate

References

  1. Bergoug M, Doudeau M, Godin F, Mosrin C, Vallee B, Benedetti H. Neurofibromin Structure, Functions and Regulation. Cells. 2020 Oct 27;9(11). pii: cells9112365. doi: 10.3390/cells9112365. PMID:33121128 doi:http://dx.doi.org/10.3390/cells9112365
  2. Naschberger A, Baradaran R, Rupp B, Carroni M. The structure of neurofibromin isoform 2 reveals different functional states. Nature. 2021 Nov;599(7884):315-319. doi: 10.1038/s41586-021-04024-x. Epub 2021, Oct 27. PMID:34707296 doi:http://dx.doi.org/10.1038/s41586-021-04024-x
  3. Trovo-Marqui AB, Tajara EH. Neurofibromin: a general outlook. Clin Genet. 2006 Jul;70(1):1-13. doi: 10.1111/j.1399-0004.2006.00639.x. PMID:16813595 doi:http://dx.doi.org/10.1111/j.1399-0004.2006.00639.x
  4. Hall BE, Bar-Sagi D, Nassar N. The structural basis for the transition from Ras-GTP to Ras-GDP. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12138-42. Epub 2002 Sep 4. PMID:12213964 doi:http://dx.doi.org/10.1073/pnas.192453199
  5. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X. PMID:29478615 doi:http://dx.doi.org/10.1016/B978-0-444-64076-5.00051-X
  6. Bergoug M, Doudeau M, Godin F, Mosrin C, Vallee B, Benedetti H. Neurofibromin Structure, Functions and Regulation. Cells. 2020 Oct 27;9(11). pii: cells9112365. doi: 10.3390/cells9112365. PMID:33121128 doi:http://dx.doi.org/10.3390/cells9112365
  7. Naschberger A, Baradaran R, Rupp B, Carroni M. The structure of neurofibromin isoform 2 reveals different functional states. Nature. 2021 Nov;599(7884):315-319. doi: 10.1038/s41586-021-04024-x. Epub 2021, Oct 27. PMID:34707296 doi:http://dx.doi.org/10.1038/s41586-021-04024-x
  8. Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7497-502. doi:, 10.1073/pnas.1607298113. Epub 2016 Jun 16. PMID:27313208 doi:http://dx.doi.org/10.1073/pnas.1607298113
  9. Frech M, Darden TA, Pedersen LG, Foley CK, Charifson PS, Anderson MW, Wittinghofer A. Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: an experimental and theoretical study. Biochemistry. 1994 Mar 22;33(11):3237-44. doi: 10.1021/bi00177a014. PMID:8136358 doi:http://dx.doi.org/10.1021/bi00177a014
  10. Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y, Raught B, Zhang ZY, Zadeh G, Ohh M. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun. 2015 Nov 30;6:8859. doi: 10.1038/ncomms9859. PMID:26617336 doi:http://dx.doi.org/10.1038/ncomms9859
  11. Lupton CJ, Bayly-Jones C, D'Andrea L, Huang C, Schittenhelm RB, Venugopal H, Whisstock JC, Halls ML, Ellisdon AM. The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. Nat Struct Mol Biol. 2021 Dec;28(12):982-988. doi: 10.1038/s41594-021-00687-2., Epub 2021 Dec 9. PMID:34887559 doi:http://dx.doi.org/10.1038/s41594-021-00687-2
  12. Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med. 2014 Jul-Sep;18(3):297-306. PMID:25182393
  13. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X. PMID:29478615 doi:http://dx.doi.org/10.1016/B978-0-444-64076-5.00051-X
  14. Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am. 2019 Nov;103(6):1035-1054. doi: 10.1016/j.mcna.2019.07.004. PMID:31582003 doi:http://dx.doi.org/10.1016/j.mcna.2019.07.004
  15. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. doi:, 10.1016/j.bbamcr.2006.10.001. Epub 2006 Oct 7. PMID:17126425 doi:http://dx.doi.org/10.1016/j.bbamcr.2006.10.001

Proteopedia Page Contributors and Editors (what is this?)

Jordyn K. Lenard, Ryan D. Adkins, Michal Harel, OCA, Jaime Prilusky

Personal tools